Posted by Michael Wonder on 07 Jun 2018
Pfizer wins appeal against £84m UK fine over epilepsy drug price
7 June 2018 - Tribunal finds competition watchdog was wrong in its market dominance conclusions.
US drugmaker Pfizer has won its appeal against an £84.2m fine imposed by the UK’s competition regulator for sharply increasing the price of an epilepsy drug.
The Competition and Markets Authority had ruled in December 2016 that Pfizer and the distributor Flynn Pharma had abused their dominant market position to raise prices for the capsule form of phenytoin sodium, an anti-seizure drug.
